...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Novel markers in zero-hour kidney biopsies indicate graft quality and clinical outcome.
【24h】

Novel markers in zero-hour kidney biopsies indicate graft quality and clinical outcome.

机译:零小时肾脏活检中的新型标记物指示移植物质量和临床结果。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: In renal transplantation, allograft biopsies provide valuable diagnostic information indicating adverse allograft outcome posttransplantation. To uncover novel candidate markers characteristic of subtle inflammation and immune activation present during the intraoperative period, we investigated messenger RNA (mRNA) gene expression profiles in renal zero biopsies. METHODS: Transcription profiles from deceased donors (n=63) and living donors (n=26) were investigated for inflammation-associated markers in zero-hour biopsies by real-time reverse-transcriptase polymerase chain reaction. RESULTS: We observed a significant induction of the chemokine receptor 7 ligands [C-C motif] ligand 19/21 in the deceased donor group (P<0.001). Additionally, along with the induction of the activation marker CD69 (P<0.01), we further detected significant elevated mRNA levels of the inducible immunoproteasome subunits PSMB8, PSMB9, and PSMB10 (P<0.001, respectively). Candidate markers were further tested for posttransplantation clinical outcomes showing the potential to predict the development of delayed graft function, acute rejection, and renal function after 6 months. For instance, by combining mRNA gene expression profiles with clinical patient data, the analysis revealed high sensitivity (95%) and specificity (84%, area under the curve=0.93) for the prediction of acute rejection. CONCLUSIONS: Zero-hour biopsies of renal allografts may provide useful information on subclinical pathological changes in the grafted kidney. The identification of CCL19/21 or PSMB8/9/10 makes these molecules particularly suitable as potential candidate targets for therapeutic interventions.
机译:背景:在肾移植中,同种异体活检提供有价值的诊断信息,表明移植后异体移植结果不良。为了揭示术中存在的微妙炎症和免疫激活特征的新候选标记,我们调查了肾脏零活检中的信使RNA(mRNA)基因表达谱。方法:通过实时逆转录酶聚合酶链反应,在零小时活检中调查了已故供体(n = 63)和活体供体(n = 26)的转录谱中炎症相关标记。结果:我们观察到已故供体组中趋化因子受体7配体[C-C基序]配体19/21的显着诱导(P <0.001)。此外,与激活标记CD69的诱导(P <0.01)一起,我们进一步检测到可诱导的免疫蛋白酶亚基PSMB8,PSMB9和PSMB10的mRNA水平显着升高(分别为P <0.001)。进一步测试了候选标记物的移植后临床结局,显示了预测6个月后移植物功能延迟,急性排斥反应和肾功能发展的潜力。例如,通过将mRNA基因表达谱与临床患者数据相结合,该分析显示出高灵敏度(95%)和特异性(84%,曲线下面积= 0.93)可用于预测急性排斥反应。结论:异体移植肾的零小时活检可能为移植肾的亚临床病理变化提供有用的信息。 CCL19 / 21或PSMB8 / 9/10的鉴定使这些分子特别适合作为治疗干预的潜在候选靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号